Lisa Holer

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub et al. · Scientific Reports · 2023 · 43 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study

Alfredo Addeo, Sacha I. Rothschild, Lisa Holer et al. · Lung Cancer · 2022 · 18 citations · Full text

Medicine, Oncology, Pharmacology +13

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Ilaria Colombo, Kira‐Lee Koster, Lisa Holer et al. · European Journal of Cancer · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +13